FRESITA PROTEINS

Which are the latest news on FRESITA PROTEINS?

Why is Sarda Proteins Ltd falling/rising?

As of 05-Sep, Sarda Proteins Ltd's stock price is at 92.66, showing a decline of 4.99% over the past week and 5.24% over the past month. Despite increased investor participation, the stock's performance remains weak, with mixed signals regarding momentum.

As of 05-Sep, Sarda Proteins Ltd's stock price is currently at 92.66, with no change from the previous close. The stock has experienced a decline of 4.99% over the past week and 5.24% over the past month, indicating a downward trend. Today, the stock opened with a loss of 4.99%, reaching an intraday low of Rs 92.66, and has not traded above this price since opening. <BR><BR>Additionally, the stock has underperformed its sector by 4.51% today and has shown erratic trading patterns, not trading on 4 out of the last 20 days. Although there has been a significant increase in investor participation, with delivery volume rising by 2808.87% compared to the 5-day average, the overall performance remains weak. The stock is trading higher than its 20-day, 50-day, and 200-day moving averages but lower than its 5-day and 100-day moving averages, suggesting mixed signals in terms of momentum. <BR><BR>Overall, the combination of recent price declines, underperformance relative to the sector, and erratic trading behavior contributes to the current falling trend of Sarda Proteins Ltd's stock price.

Who are in the management team of Sarda Proteins?

The management team of Sarda Proteins includes Vanita Bhanot (Non-Executive & Non-Independent Director), Deepak Data (Managing Director), Amit Kumar Modi (Company Secretary & Compliance Officer), Tarun Kumar Taunk (Non-Executive & Independent Director), and Mahavir Pratap Sharma (Non-Executive & Independent Director).

The management team of Sarda Proteins includes the following members:<BR><BR>1. **Vanita Bhanot** - Non-Executive & Non-Independent Director<BR>2. **Deepak Data** - Managing Director<BR>3. **Amit Kumar Modi** - Company Secretary & Compliance Officer<BR>4. **Tarun Kumar Taunk** - Non-Executive & Independent Director<BR>5. **Mahavir Pratap Sharma** - Non-Executive & Independent Director<BR><BR>If you have any more questions about Sarda Proteins or its management, feel free to ask!

What does Sarda Proteins do?

Sarda Proteins Ltd is a micro-cap company engaged in trading edible oils and agri commodities, with recent net sales of ₹13 Cr and net profit of ₹2 Cr as of June 2026. The company was incorporated in 1991 and underwent a management change in 2018.

Overview:<BR>Sarda Proteins Ltd is primarily engaged in the trading of edible oils and agri commodities, operating within the edible oil industry and classified as a micro-cap company.<BR><BR>History:<BR>Sarda Proteins Limited was incorporated on December 03, 1991. The company underwent a management change in FY 2018-19 following the acquisition by Ritika Vegetable Oil Private Limited. The latest reported quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 13 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap value: INR 83 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -2.44<BR>- Return on Equity: 92.36%<BR>- Price to Book: 29.08<BR><BR>Contact Details:<BR>Address: B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030<BR>Tel: 91-144-2881392<BR>Email: sardaproteins@yahoo.com<BR>Website: http://www.sardaproteins.com

Who are the peers of the Sarda Proteins?

Sarda Proteins' peers include M K Proteins, Prime Industries, Raj Oil Mills, Diligent Industries, N K Industries, and Rajgor Castor. Key insights show Rajgor Castor has excellent management risk and growth, while Sarda Proteins has below-average growth and good capital structure, with a 1-year return of N/A for comparison.

Peers: The peers of Sarda Proteins are M K Proteins, Prime Industries, Raj Oil Mills, Diligent Indust., N K Industries, Rajgor Castor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Rajgor Castor, while Average management risk is found at M K Proteins and the rest. Below Average management risk is noted at Prime Industries, Sarda Proteins, Diligent Indust., and the rest. Growth is Excellent at Prime Industries and Rajgor Castor, while Good growth is seen at Diligent Indust., and Below Average growth is present at M K Proteins, Sarda Proteins, and the rest. Capital Structure is Excellent at M K Proteins and Prime Industries, Good at Sarda Proteins, and Below Average at Diligent Indust., with the rest not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suraj Industries at 28.18%, while Sarda Proteins has a 1-year return of N/A, indicating it cannot be compared directly. The peer with the lowest 1-year return is M K Proteins at -36.50%. Additionally, Diligent Indust. and N K Industries have negative six-month returns.

How big is Sarda Proteins?

As of 31st August, Sarda Proteins Ltd has a market capitalization of 83.00 Cr, with recent net sales of 18.19 Cr and a net profit of 2.78 Cr. Shareholder's funds are 2.38 Cr and total assets are 2.53 Cr as of March 2025.

As of 31st August, Sarda Proteins Ltd has a market capitalization of 83.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sarda Proteins reported Net Sales of 18.19 Cr and a Net Profit of 2.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2.38 Cr and Total Assets of 2.53 Cr.

Should I buy, sell or hold Sarda Proteins Ltd?

When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is April 30, 2026.

The next results date for Sarda Proteins Ltd is scheduled for April 30, 2026.

How has been the historical performance of Sarda Proteins?

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Is Sarda Proteins overvalued or undervalued?

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

What is the technical trend for Sarda Proteins?

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.